Cerenkov luminescence imaging for radiation dose calculation of a 90Y-labeled gastrin-releasing peptide receptor

Journal of Nuclear Medicine

Volumn 56, Issue 5, 2015, Pages 805-811

  Lohrmann, Christian ^a   Zhang, Hanwen ^a   Thorek, Daniel L J ^b   Desai, Pooja ^a   Zanzonico, Pat B ^a   O'Donoghue, Joseph ^a   Irwin, Christopher P ^a   Reiner, Thomas ^a   Grimm, Jan ^a   Weber, Wolfgang A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

90Y; Cerenkov luminescence imaging; Gastrin releasing peptide receptor; Targeted radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM DOTA AR Y 90; BOMBESIN RECEPTOR; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND; YTTRIUM(III)-1,4,7,10-TETRAAZACYCLOTETRADECANE-N,N',N'',N'''-TETRAACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CERENKOV LUMINESCENCE IMAGING; CERENKOV RADIATION; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STRUCTURE; EX VIVO STUDY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMAGING; IN VIVO STUDY; ISOTOPE LABELING; LIQUID SCINTILLATION COUNTING; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIATION ABSORPTION; RADIOACTIVITY; RADIOLOGICAL PARAMETERS; TIME SERIES ANALYSIS; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; FLUORESCENCE IMAGING; LUMINESCENCE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HETEROCYCLIC COMPOUNDS; HUMANS; LUMINESCENCE; MALE; MICE; OPTICAL IMAGING; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RECEPTORS, BOMBESIN;

EID: 84929459660     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.149054     Document Type: Article

References (34)

1. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent Trial. J Clin Oncol. 2013;31: 1977-1983.
2. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2):42S-55S.
3. Evans KA, Richardson MG, Pavlakis N, et al. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol. 2010;21:1521-1526.
4. 90Y bremsstrahlung SPECT method. Med Phys. 2012;39:2346-2358.
5. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med. 2010;51:1974-1978.
6. Elschot M, Vermolen BJ, Lam MG, de Keizer B, van den Bosch MA, de Jong HW. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS ONE. 2013;8:e55742.
7. Rong X, Du Y, Frey EC. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging. Phys Med Biol. 2012;57:3711-3725.
8. Cherenkov PA. Visible emission of clean liquids by action of gamma-radiation. Dokl Akad Nauk SSSR. 1934;2:451-452.
9. Thorek DLJ, Robertson R, Bacchus WA, et al. Cerenkov imaging: a new modality for molecular imaging. Am J Nucl Med Mol Imaging. 2012;2:163-173.
10. Ruggiero A, Holland JP, Lewis JS, Grimm J. Cerenkov luminescence imaging of medical isotopes. J Nucl Med. 2010;51:1123-1130.
11. Spinelli AE, D'Ambrosio D, Calderan L, Marengo M, Sbarbati A, Boschi F. Cerenkov radiation allows in vivo optical imaging of positron emitting radio-tracers. Phys Med Biol. 2010;55:483-495.
12. Holland JP, Normand G, Ruggiero A, Lewis JS, Grimm J. Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. Mol Imaging. 2011;10:177-186.
13. Liu H, Carpenter CM, Jiang H, et al. Intraoperative imaging of tumors using Cerenkov luminescence endoscopy: a feasibility experimental study. J Nucl Med. 2012;53:1579-1584.
14. Chin PT, Welling MM, Meskers SC, Valdes Olmos RA, Tanke H, van Leeuwen FW. Optical imaging as an expansion of nuclear medicine: Cerenkov-based luminescence vs fluorescence-based luminescence. Eur J Nucl Med Mol Imaging. 2013;40:1283-1291.
15. Liu H, Ren G, Miao Z, et al. Molecular optical imaging with radioactive probes. PLoS ONE. 2010;5:e9470.
16. Carpenter CM, Ma X, Liu H, et al. Cerenkov luminescence endoscopy: improved molecular sensitivity with β-emitting radiotracers. J NuclMed.2014;55:1905-1909.
17. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
18. Abiraj K, Mansi R, Tamma ML, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011;52:1970-1978.
19. Bardiès M, Chatal JF. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys Med Biol. 1994;39:961-981.
20. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240-5249.
21. Schroeder RP, Müller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1386-1396.
22. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
23. 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52:470-477.
24. Yang M, Gao H, Zhou Y, et al. F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2011;1:220-229.
25. Dumont RA, Tamma M, Braun F, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med. 2013;54:762-769.
26. Mansi R, Fleischmann A, Mäcke HR, Reubi JC. Targeting GRPR in urological cancers: from basic research to clinical application. Nat Rev Urol. 2013;10:235-244.
27. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
28. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR, Silva MD. Optical imaging of Cerenkov light generation from positron-emitting radiotracers. Phys Med Biol. 2009;54:N355-N365.
29. Mitchell GS, Gill RK, Boucher DL, Li C, Cherry SR. In vivo Cerenkov luminescence imaging: a new tool for molecular imaging. Philos Transact A Math Phys Eng Sci. 2011;369:4605-4619.
30. Thorek DLJ, Ogirala A, Beattie BJ, Grimm J. Quantitative imaging of disease signatures through radioactive decay signal conversion. Nat Med. 2013;19:1345-1350.
31. Spinelli AE, Ferdeghini M, Cavedon C, et al. First human Cerenkography. J Biomed Opt. 2013;18:20502.
32. 18F-FDG. J Nucl Med. 2014;55:95-98.
33. Beattie BJ, Thorek DLJ, Schmidtlein CR, Pentlow KS, Humm JL, Hielscher AH. Quantitative modeling of Cerenkov light production efficiency from medical radionuclides. PLoS ONE. 2012;7:e31402.
34. Nayak TK, Brechbiel MW. 86Y based PET radiopharmaceuticals: radiochemistry and biological applications. Med Chem. 2011;7:380-388.